Unknown

Dataset Information

0

Novel antidotes for target specific oral anticoagulants.


ABSTRACT: Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.

SUBMITTER: Das A 

PROVIDER: S-EPMC4570637 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel antidotes for target specific oral anticoagulants.

Das Arundhati A   Liu Delong D  

Experimental hematology & oncology 20150915


Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977. ...[more]

Similar Datasets

| S-EPMC4167197 | biostudies-literature
| S-EPMC6186922 | biostudies-literature
| S-EPMC4711499 | biostudies-literature
| S-EPMC5315223 | biostudies-other
| S-EPMC2274902 | biostudies-other
| S-EPMC7649461 | biostudies-literature
| S-EPMC3726366 | biostudies-literature
| S-EPMC7196985 | biostudies-literature
| S-EPMC6404908 | biostudies-literature
| S-EPMC4321075 | biostudies-other